Literature DB >> 19593598

Characterization of two novel SETX mutations in AOA2 patients reveals aspects of the pathophysiological role of senataxin.

Giovanni Airoldi1, Andrea Guidarelli, Orazio Cantoni, Chris Panzeri, Chiara Vantaggiato, Sara Bonato, Maria Grazia D'Angelo, Sestina Falcone, Clara De Palma, Alessandra Tonelli, Claudia Crimella, Sara Bondioni, Nereo Bresolin, Emilio Clementi, Maria Teresa Bassi.   

Abstract

Ataxia with oculomotor apraxia (AOA) type 2 (AOA2 MIM 606002) is a recessive subtype of AOA characterized by cerebellar atrophy, oculomotor apraxia, early loss of reflexes, and peripheral neuropathy. Various mutations either in homozygous or compound heterozygous condition were so far identified in the associated gene SETX (MIM 608465). SETX encodes a large protein called senataxin with a DNA-RNA helicase domain and a putative N-terminus protein interaction domain. Here, we report the identification of two novel homozygous mutations in SETX gene, c.340_342delCTT (p.L114Del) and c.1669C > T (p.R557X), in two AOA2 families. The characterization of the mutant lymphoblastoid cell lines for sensitivity to oxidative DNA-damaging agents indicates that the p.L114Del deletion confers an increased sensitivity to H2O2, camptothecin, and mitomycin C, previously found to induce death in lymphoblasts harbouring other SETX mutations; the cells carrying the nonsense mutation display instead values within the normal range. Further analysis of a neuronal cell model SKNBE, transfected with the mutant senataxin proteins, reveals increased sensitivity also to staurosporine and excitotoxicity associated with the p.L114Del mutant only. We also demonstrate that the sensitizing effect of p.L114Del on apoptosis can be reversed by senataxin silencing. The ability of a single amino acid deletion to sensitize cells to death by different agents, compared to the lack of effect of a whole protein deletion, seems to exclude a protective role played by the native protein while suggesting that a specific mutation confers to the protein the ability to enhance the toxic effect of various cell damaging agents.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19593598     DOI: 10.1007/s10048-009-0206-0

Source DB:  PubMed          Journal:  Neurogenetics        ISSN: 1364-6745            Impact factor:   2.660


  30 in total

1.  Ataxia with oculomotor apraxia type 2: a clinical, pathologic, and genetic study.

Authors:  C Criscuolo; L Chessa; S Di Giandomenico; P Mancini; F Saccà; G S Grieco; M Piane; F Barbieri; G De Michele; S Banfi; F Pierelli; N Rizzuto; F M Santorelli; L Gallosti; A Filla; C Casali
Journal:  Neurology       Date:  2006-04-25       Impact factor: 9.910

Review 2.  New autosomal recessive cerebellar ataxias with oculomotor apraxia.

Authors:  Isabelle Le Ber; Alexis Brice; Alexandra Dürr
Journal:  Curr Neurol Neurosci Rep       Date:  2005-09       Impact factor: 5.081

3.  The tyrosyl-DNA phosphodiesterase Tdp1 is a member of the phospholipase D superfamily.

Authors:  H Interthal; J J Pouliot; J J Champoux
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-25       Impact factor: 11.205

Review 4.  Clinical features and molecular genetics of autosomal recessive cerebellar ataxias.

Authors:  Brent L Fogel; Susan Perlman
Journal:  Lancet Neurol       Date:  2007-03       Impact factor: 44.182

5.  Autosomal recessive ataxia with peripheral neuropathy and elevated AFP: novel mutations in SETX.

Authors:  T Asaka; H Yokoji; J Ito; K Yamaguchi; A Matsushima
Journal:  Neurology       Date:  2006-05-23       Impact factor: 9.910

6.  The first ALS2 missense mutation associated with JPLS reveals new aspects of alsin biological function.

Authors:  Chris Panzeri; Clara De Palma; Andrea Martinuzzi; Andrea Daga; Gianni De Polo; Nereo Bresolin; Christopher C Miller; Elizabeth L Tudor; Emilio Clementi; Maria T Bassi
Journal:  Brain       Date:  2006-05-02       Impact factor: 13.501

7.  Identification and characterisation of a large senataxin (SETX) gene duplication in ataxia with ocular apraxia type 2 (AOA2).

Authors:  Larissa Arning; Ludger Schöls; Huriye Cin; Manfred Souquet; Jörg T Epplen; Dagmar Timmann
Journal:  Neurogenetics       Date:  2008-07-29       Impact factor: 2.660

8.  Senataxin, the ortholog of a yeast RNA helicase, is mutant in ataxia-ocular apraxia 2.

Authors:  Maria-Céu Moreira; Sandra Klur; Mitsunori Watanabe; Andrea H Németh; Isabelle Le Ber; José-Carlos Moniz; Christine Tranchant; Patrick Aubourg; Meriem Tazir; Lüdger Schöls; Massimo Pandolfo; Jörg B Schulz; Jean Pouget; Patrick Calvas; Masami Shizuka-Ikeda; Mikio Shoji; Makoto Tanaka; Louise Izatt; Christopher E Shaw; Abderrahim M'Zahem; Eimear Dunne; Pascale Bomont; Traki Benhassine; Naïma Bouslam; Giovanni Stevanin; Alexis Brice; João Guimarães; Pedro Mendonça; Clara Barbot; Paula Coutinho; Jorge Sequeiros; Alexandra Dürr; Jean-Marie Warter; Michel Koenig
Journal:  Nat Genet       Date:  2004-02-08       Impact factor: 38.330

9.  A novel c.5308_5311delGAGA mutation in Senataxin in a Cypriot family with an autosomal recessive cerebellar ataxia.

Authors:  Paschalis Nicolaou; Anthi Georghiou; Christina Votsi; Lefkos T Middleton; Eleni Zamba-Papanicolaou; Kyproula Christodoulou
Journal:  BMC Med Genet       Date:  2008-04-14       Impact factor: 2.103

10.  Senataxin, defective in ataxia oculomotor apraxia type 2, is involved in the defense against oxidative DNA damage.

Authors:  Amila Suraweera; Olivier J Becherel; Philip Chen; Natalie Rundle; Rick Woods; Jun Nakamura; Magtouf Gatei; Chiara Criscuolo; Alessandro Filla; Luciana Chessa; Markus Fusser; Bernd Epe; Nuri Gueven; Martin F Lavin
Journal:  J Cell Biol       Date:  2007-06-11       Impact factor: 10.539

View more
  8 in total

1.  (1)H MR spectroscopy in Friedreich's ataxia and ataxia with oculomotor apraxia type 2.

Authors:  Isabelle Iltis; Diane Hutter; Khalaf O Bushara; H Brent Clark; Myron Gross; Lynn E Eberly; Christopher M Gomez; Gülin Oz
Journal:  Brain Res       Date:  2010-08-14       Impact factor: 3.252

2.  Unique Ataxia-Oculomotor Apraxia 2 (AOA2) in Israel with Novel Variants, Atypical Late Presentation, and Possible Identification of a Poison Exon.

Authors:  Vardiella Meiner; Alexander Lossos; Hagit Baris Feldman; Penina Ponger; Alina Kurolap; Israela Lerer; Judith Dagan; Chofit Chai Gadot; Adi Mory; Yael Wilnai; Nino Oniashvili; Nir Giladi; Tanya Gurevich
Journal:  J Mol Neurosci       Date:  2022-06-08       Impact factor: 2.866

3.  Ataxia with oculomotor apraxia type 2 fibroblasts exhibit increased susceptibility to oxidative DNA damage.

Authors:  Ricardo H Roda; Carlo Rinaldi; Rajat Singh; Alice B Schindler; Craig Blackstone
Journal:  J Clin Neurosci       Date:  2014-05-06       Impact factor: 1.961

4.  A new model to study neurodegeneration in ataxia oculomotor apraxia type 2.

Authors:  Olivier J Becherel; Jane Sun; Abrey J Yeo; Sam Nayler; Brent L Fogel; Fuying Gao; Giovanni Coppola; Chiara Criscuolo; Giuseppe De Michele; Ernst Wolvetang; Martin F Lavin
Journal:  Hum Mol Genet       Date:  2015-07-30       Impact factor: 6.150

5.  Next-generation sequencing study reveals the broader variant spectrum of hereditary spastic paraplegia and related phenotypes.

Authors:  Ewelina Elert-Dobkowska; Iwona Stepniak; Wioletta Krysa; Karolina Ziora-Jakutowicz; Maria Rakowicz; Anna Sobanska; Jacek Pilch; Dorota Antczak-Marach; Jacek Zaremba; Anna Sulek
Journal:  Neurogenetics       Date:  2019-02-19       Impact factor: 2.660

6.  SETX sumoylation: A link between DNA damage and RNA surveillance disrupted in AOA2.

Authors:  Patricia Richard; James L Manley
Journal:  Rare Dis       Date:  2014-01-21

7.  Senataxin resolves RNA:DNA hybrids forming at DNA double-strand breaks to prevent translocations.

Authors:  Sarah Cohen; Nadine Puget; Yea-Lih Lin; Thomas Clouaire; Marion Aguirrebengoa; Vincent Rocher; Philippe Pasero; Yvan Canitrot; Gaëlle Legube
Journal:  Nat Commun       Date:  2018-02-07       Impact factor: 14.919

8.  Molecular Characterization of Portuguese Patients with Hereditary Cerebellar Ataxia.

Authors:  Mariana Santos; Joana Damásio; Susana Carmona; João Luís Neto; Nadia Dehghani; Leonor Correia Guedes; Clara Barbot; José Barros; José Brás; Jorge Sequeiros; Rita Guerreiro
Journal:  Cells       Date:  2022-03-12       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.